NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
43
Stocks News & Analysis
stocks
After earnings, is Uber stock a buy, a sell, or fairly valued?
stocks
The largest share trading on the ASX remains materially overvalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,115.90 | 1.50 | -0.02% |
| CAC 40 | 8,156.23 | 0.00 | 0.00% |
| DAX 40 | 24,088.06 | 128.07 | 0.53% |
| Dow JONES (US) | 47,927.96 | 559.33 | 1.18% |
| FTSE 100 | 9,899.60 | 112.45 | 1.15% |
| HKSE | 26,835.87 | 139.46 | 0.52% |
| NASDAQ | 23,468.30 | 58.87 | -0.25% |
| Nikkei 225 | 50,889.32 | 46.39 | 0.09% |
| NZX 50 Index | 13,679.07 | 74.52 | 0.55% |
| S&P 500 | 6,846.61 | 14.18 | 0.21% |
| S&P/ASX 200 | 8,836.60 | 0.60 | 0.01% |
| SSE Composite Index | 3,999.94 | 2.81 | -0.07% |